Piper Jaffray Companies set a $435.00 target price on Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note released on Tuesday morning, TipRanks reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.
REGN has been the topic of a number of other research reports. BMO Capital Markets set a $344.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a hold rating in a research report on Tuesday. JPMorgan Chase & Co. restated a hold rating on shares of Regeneron Pharmaceuticals in a research report on Friday, June 21st. Leerink Swann set a $453.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, June 11th. Canaccord Genuity lowered their price objective on shares of Regeneron Pharmaceuticals from $353.00 to $320.00 and set a hold rating on the stock in a research report on Wednesday. Finally, Cowen restated a hold rating and set a $353.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, July 29th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $394.56.
Shares of NASDAQ:REGN traded up $2.41 during trading on Tuesday, reaching $300.77. 969,328 shares of the stock traded hands, compared to its average volume of 773,155. The stock has a 50-day moving average of $286.11 and a two-hundred day moving average of $315.65. Regeneron Pharmaceuticals has a 52-week low of $271.37 and a 52-week high of $442.00. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.11 and a current ratio of 3.88. The stock has a market cap of $31.31 billion, a P/E ratio of 15.19, a price-to-earnings-growth ratio of 1.30 and a beta of 1.14.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $5.29 earnings per share for the quarter, beating the Zacks’ consensus estimate of $4.60 by $0.69. The company had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.80 billion. Regeneron Pharmaceuticals had a net margin of 28.59% and a return on equity of 25.79%. The firm’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.45 earnings per share. Sell-side analysts expect that Regeneron Pharmaceuticals will post 19.22 earnings per share for the current year.
In other Regeneron Pharmaceuticals news, major shareholder Sanofi sold 172,904 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $281.15, for a total value of $48,611,959.60. 11.84% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in REGN. Buckingham Capital Management Inc. bought a new position in Regeneron Pharmaceuticals in the first quarter worth approximately $969,000. First Trust Advisors LP raised its position in shares of Regeneron Pharmaceuticals by 23.9% during the 1st quarter. First Trust Advisors LP now owns 360,562 shares of the biopharmaceutical company’s stock valued at $148,054,000 after purchasing an additional 69,493 shares during the period. Wealthfront Advisers LLC raised its position in shares of Regeneron Pharmaceuticals by 41.8% during the 1st quarter. Wealthfront Advisers LLC now owns 1,490 shares of the biopharmaceutical company’s stock valued at $612,000 after purchasing an additional 439 shares during the period. Westwood Holdings Group Inc. raised its position in shares of Regeneron Pharmaceuticals by 48.1% during the 1st quarter. Westwood Holdings Group Inc. now owns 7,313 shares of the biopharmaceutical company’s stock valued at $3,003,000 after purchasing an additional 2,374 shares during the period. Finally, Andra AP fonden bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $5,995,000. Institutional investors and hedge funds own 66.54% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Article: What is the Stochastic Momentum Index (SMI)?
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.